

Showcasing research from Professor Anna Herland's *in-vitro* neural systems laboratory at the KTH Royal Institute of Technology & Karolinska Institute, Stockholm, Sweden.

Low-cost microphysiological systems: feasibility study of a tape-based barrier-on-chip for small intestine modeling

High costs are a key challenge in "democratization" of organ-chip research. We present a low-resource barrier-on-chip based on tape, and use it to model the small intestine and its response to chili peppers (capsaicinoids).

### As featured in:



See Thomas E. Winkler,  
Anna Herland *et al.*,  
*Lab Chip*, 2020, **20**, 1212.



Cite this: *Lab Chip*, 2020, **20**, 1212

## Low-cost microphysiological systems: feasibility study of a tape-based barrier-on-chip for small intestine modeling†

Thomas E. Winkler, <sup>\*a</sup> Michael Feil, <sup>ab</sup> Eva F. G. J. Stronkman, <sup>‡ac</sup>  
 Isabelle Matthiesen <sup>a</sup> and Anna Herland <sup>\*ad</sup>

We see affordability as a key challenge in making organs-on-chips accessible to a wider range of users, particularly outside the highest-resource environments. Here, we present an approach to barrier-on-a-chip fabrication based on double-sided pressure-sensitive adhesive tape and off-the-shelf polycarbonate. Besides a low materials cost, common also to PDMS or thermoplastics, it requires minimal (€100) investment in laboratory equipment, yet at the same time is suitable for upscaling to industrial roll-to-roll manufacture. We evaluate our microphysiological system with an epithelial (Caco-2/BBe1) barrier model of the small intestine, studying the biological effects of permeable support pore size, as well as stimulation with a common food compound (chili pepper-derived capsaicinoids). The cells form tight and continuous barrier layers inside our systems, with comparable permeability but superior epithelial polarization compared to Transwell culture, in line with other perfused microphysiological models. Permeable support pore size is shown to weakly impact barrier layer integrity as well as the metabolic cell profile. Capsaicinoid response proves distinct between culture systems, but we show that impacted metabolic pathways are partly conserved, and that cytoskeletal changes align with previous studies. Overall, our tape-based microphysiological system proves to be a robust and reproducible approach to studying physiological barriers, in spite of its low cost.

Received 5th January 2020,  
 Accepted 1st March 2020

DOI: 10.1039/d0lc00009d

rsc.li/loc

### Introduction

Microphysiological systems have the potential to reduce animal testing, to accelerate drug development, and to study cellular processes that are simply not accessible in live humans.<sup>1</sup> To date, however, high costs represent a significant barrier to entry into the field (Table 1). This applies, on the one hand, to commercial solutions. Companies like Emulate or TissUse have surmounted scalability challenges, yet costs remain high. It applies, on the other hand, also to in-house fabrication of organs-on-chips in an academic setting. Set-up even for the predominantly-used poly(dimethylsiloxane) (PDMS)-based processing can be prohibitive for researchers in low-resource environments. Indeed, research from the top ten countries in terms of per-capita research spending accounts

for 78% of the primary literature on organs-on-chips (compared to only 51% for broadly-defined *in vitro* research, or 59% for labs-on-chips; data as of 2019).<sup>2,3</sup>

We see the current high-resource fabrication requirements for organs-on-chips as the key barrier to “democratization” of the field. Unlike labs-on-chips, microphysiological systems almost exclusively require integration of disparate materials – all capable of supporting cell culture – to create biomimetic compartmentalization. Prime examples are epithelial or endothelial barrier models, which make up the largest fraction of modeled organs.<sup>4</sup> One review paper for blood–brain-barrier devices – exemplary of the larger field – shows that fabrication is dominated by combinations of glass, PDMS, and thermoplastics.<sup>5</sup> Even the simplest bonding scenario of glass/PDMS needs to be facilitated by external means (plasma), requiring additional equipment and making scale-up challenging.

Double-coated pressure-sensitive adhesive tape (hereafter, tape) offers an ideal solution to the challenges described. First, it is a very affordable material that can be patterned with minimal cost (a scalpel and steady hand, or a vinyl cutter). Yet processing at industrial scale is well-established with roll-to-roll die-cutting and pick-and-place alignment (common e.g. for solar cells or fuel cell membranes).<sup>6–8</sup> Second, it features intrinsic bonding capabilities to a wide

<sup>a</sup> Division of Micro- and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden. E-mail: [winklert@kth.se](mailto:winklert@kth.se), [aherland@kth.se](mailto:aherland@kth.se)

<sup>b</sup> University of Applied Sciences Campus Vienna, Vienna, Austria

<sup>c</sup> Saxion University of Applied Sciences, Enschede, The Netherlands

<sup>d</sup> AIMES, Department of Neuroscience, Karolinska Institute, Solna, Sweden

† Electronic supplementary information (ESI) available. See DOI: [10.1039/d0lc00009d](https://doi.org/10.1039/d0lc00009d)

‡ Current affiliation: Department of Bioengineering, Twente University, Enschede, The Netherlands.



**Table 1** Overview of barrier-on-chip approaches & costs

	Tape (this work)	PDMS	Thermoplastics
Base materials cost/“organ”	€0.5	€0.3	€0.2
Tooling cost <sup>a</sup>	€0	€100+	€1000+
Equipment cost <sup>a</sup>	€100–1000+	€1000–10 000+	€5000–50 000+
Assembly aides	Pressure only	Plasma, chemical	Heat + pressure, chemical
Scalability <sup>b</sup>	Roll-to-roll	Difficult	Inherently
Commercial product <sup>c</sup>	None	>€100/“organ”	>€7/“organ”

<sup>a</sup> Tooling costs include molds, dies, *etc.*; equipment costs include knife/laser cutters, desiccators, plasma chambers, injection presses, *etc.*; both are assessed for academic scenarios. <sup>b</sup> This refers to the materials' potential for scaling up chip manufacturing/translating processes into an industrial setting, toward commercial production. <sup>c</sup> Refer to ESI† Table S1 for extended overview, including the caveats of commercial thermoplastic systems in the low-cost regime.

range of materials that may be required – glass, metals, and plastics. Tape microfluidics have previously been demonstrated in a lab-on-chip setting.<sup>9,10</sup> The requirements for organs-on-chips, however, are higher due to live biological elements as mentioned earlier. Kratz *et al.* only recently presented an excellent characterization of tapes for organ-on-chip use, and demonstrated HUVEC culture in a single-compartment chip.<sup>11</sup> Yet no study to date – including theirs – has implemented a tape-based multi-compartment system, or barrier-on-chip specifically, and demonstrated its biological functionality.

Here, we present the first such study by investigating two candidate tapes and two fabrication methods for their compatibility with epithelial barrier cells. Using commercially available parts and low-cost patterning methods, we design an 8-fold multiplexed barrier-on-chip system with a per-“organ” cost of €0.5 and necessary start-up equipment costs of as low as €100 in an academic setting. We validate the system by demonstrating formation of a tight barrier over 8 days of culture in all “organs”, with good agreement compared to theory as well as barriers grown on gold-standard Transwell permeable supports. We assess biological function in terms of actin and tight junction protein localization as well as metabolic response as a function of permeable membrane pore size in our barriers-on-chips, as well as compared to Transwells. We further investigate stimulation of these small intestine models with capsaicinoids, the active components in chili peppers.

## Materials & methods

### Barrier-on-a-tape-chip fabrication

Double-sided medical-grade adhesive tapes 9889 and 9877 for material evaluation were kindly provided by 3M (Maplewood,

Minnesota). Since 3M provides only sample quantities or industrial-scale orders, additional 9877 tape for device manufacture was obtained from a local 3M “preferred medical converter,” Beneli AB (Helsingborg, Sweden; 3M maintains a sizable network of similar converters around the world). Key properties are summarized in Table 2. Polycarbonate (PC) membranes (25 µm thick) with track-etched pores ( $1.6 \times 10^6 \text{ cm}^{-2}$ , 0.4 µm or 1 µm diameter) were purchased from ip4it (Louvain-la-Neuve, Belgium). 125 µm thick PC foil (Makrofol DE 1-1) was kindly provided by Covestro AG (Leverkusen, Germany).

We employed a cutting plotter (CE 5000; Graphtec, Tokyo, Japan) and CO<sub>2</sub> laser (VLS 2.3; Universal Laser Systems, Scottsdale) to pattern the tape and membrane based on CAD drawings. Bonding between layers was facilitated using a hydraulic press (Rosin Tech Products, Los Angeles, CA).

### Cell culture

Human enterocytes (Caco-2/BBe1; a clone of Caco-2) were obtained from ATCC at passage 47. Frozen stocks were expanded according to supplier protocols and maintained at 37 °C/5% CO<sub>2</sub>. Cells were used at passages 50–55. Media was prepared from DMEM (high glucose; Gibco 10569010) and 100 U ml<sup>-1</sup> penicillin-streptomycin (Gibco 15140122). For the cytotoxicity assay, we supplemented the media with 20% heat-inactivated fetal bovine serum (FBS; Gibco A3840002). In the remainder of our study, we employed 10% FBS combined with 1× insulin-transferrin-selenium (ITS; Gibco 41400045). Media was prepared the day prior to use and placed in the incubator overnight to equilibrate. Pre-equilibration to 37 °C and to the “correct” partial pressures of dissolved gases reduces one potential source of

**Table 2** Key properties of the two tapes considered (source: 3M data sheets)

	3M 9889	3M 9877
Total thickness	120 µm	110 µm
Carrier	80 µm polyethylene	23 µm polyester
Adhesive	Tackified acrylic	Synthetic rubber-based
Steel adhesion	14.7 N (25 mm) <sup>-1</sup>	33.4 N (25 mm) <sup>-1</sup>
Cytotoxicity data	L-929 fibroblasts, albino rabbit, guinea pig	L-929 fibroblasts, albino rabbit, human
Sterilization	EtO, gamma	EtO, gamma, autoclave



bubble formation, a common failure mode in any organ-chip (and microfluidics in general).<sup>12</sup>

### Cytotoxicity testing

The cell coverage experiments were conducted in 24-well plates (flat bottom, TC-treated). Semicircular pieces of tapes were cut and inserted into the wells ( $N = 8$ ). In this experiment only, no attachment-supporting coatings were applied, but we relied on proteins adsorbing from the high 20% serum content in the media. Cells were seeded out over the entire well area and cultured over 8 days. We manually segmented phase contrast images to estimate cell coverage next to the tapes ( $n = 4$  images per well). The coverage analysis for growth on top of the tapes relied on threshold segmentation of the Hoechst fluorescence signal ( $n = 1$  image per well). Each image/datum corresponds to one  $9.5 \text{ mm}^2$  field of view (10% of the total available cell growth area).

### Experimental procedure

For the biological functionality study, we conducted parallel experiments with tape microfluidics ( $N = 8$ ;  $n = 4$  per membrane type) and Transwell permeable supports ( $N = 13$ ;  $n = 1$  as no-cell control) with a  $10 \mu\text{m}$ ,  $0.33 \text{ cm}^2$  polyester membrane ( $0.4 \mu\text{m}$  diameter pores;  $4 \times 10^6 \text{ cm}^{-2}$ ; Corning 3470). Transwells were coated with a mixture (prepared on ice) of  $300 \mu\text{g mL}^{-1}$  Matrikel growth factor reduced (GFR) basement membrane matrix (Corning 354230) and  $50 \mu\text{g mL}^{-1}$  Collagen I Rat Tail High Concentration (Corning 354249) to enhance cell attachment by overnight incubation at  $37^\circ\text{C}$ . After removing excess coating solution, enterocytes were seeded at  $1.5 \times 10^5 \text{ cm}^{-2}$  on top of the permeable supports along with  $200 \mu\text{L}$  media, and  $800 \mu\text{L}$  media in the bottom (basal) compartments. Media was exchanged every second day until day 8 (only half the media volume was replaced in the apical compartment).

For tape microfluidic culture, flow was provided by a 16-channel peristaltic pump (ISM 1136; Cole-Parmer, Wertheim, Germany) featuring  $0.25 \text{ mm}$  inner diameter (ID) PharMed BPT tubing. An additional  $5 \text{ cm}$  of the same tubing provided chip access on either side, and longer sections were used when recirculating media. Media reservoirs consisted of sterile-packaged  $6 \text{ mL}$  syringe bodies with blunt needles and  $12 \text{ cm}$  of  $1.6 \text{ mm}$  ID Tygon ND-100-65 tubing (Saint-Gobain, La Défense, France). Fluidic interconnects were fashioned from  $1.6 \text{ mm}$  ID tubing or  $0.2 \text{ mm}$  ID stainless steel pins (Inter alloy, Schinznach-Bad, Switzerland) as needed. Blunt needles, pins, and tubing were autoclaved before use. The pump was controlled *via* a custom LabView interface to generally provide an average forward flow of  $Q \sim 90 \mu\text{L h}^{-1}$ . More specifically, the pulsatile pumping scheme employed flow intervals at  $540 \mu\text{L h}^{-1}$  in both forward direction (60 s) and reverse (30 s). Each pulse thus corresponds to roughly 6 or 3 channel volume exchanges, respectively. Utilizing both forward and reverse directions allows us to decouple outflow

volume from shear stress. The flow was paused for 45 s between each pulse. Every six hours, the system was additionally flushed at  $2700 \mu\text{L h}^{-1}$  (10 s) to remove potential obstructions (cellular debris, nucleated bubbles) from the system.

On day -1, devices were disinfected (and cleared of bubbles) by flushing with 70% ethanol for 5 minutes. Subsequently, they were generously rinsed with PBS, again ensuring no bubbles remained in the channels. We then aspirated a collagen/Matrigel coating ( $50 \mu\text{g mL}^{-1}$  &  $300 \mu\text{g mL}^{-1}$ ) into the channels *via* pre-chilled tubing. Cell culture media reservoirs were connected, but perfusion was only started after an initial static incubation for 6 h at  $37^\circ\text{C}$ . On day 0, enterocytes were seeded in the upper channel at  $1.75 \times 10^5 \text{ cm}^{-2}$  *via* aspiration and left to attach in the incubator under static conditions for 2 hours, before re-starting perfusion. We gradually ramped up the flow to  $90 \mu\text{L h}^{-1}$  over 12 hours before switching to the aforementioned pulsed scheme. The cells were allowed to form a barrier over 8 days, with media recirculating from day 2. On day 7, recirculation was stopped and fresh media introduced.

On day 8, media was fully exchanged in all Transwell compartments and microfluidic reservoirs (including inlet connection tubing). Basally, we supplied regular media in all conditions. Apically, we supplied either regular media ( $n = 4$  Transwells), media containing  $600 \mu\text{M}$  capsaicinoids ( $n = 4$  Transwells,  $n = 6$  on-chip barriers), or media containing an equivalent amount of ethanol vehicle (0.6%;  $n = 3$  Transwells,  $n = 2$  on-chip). Conditions were distributed equally among membrane types for the devices. Capsaicinoid media was prepared by spiking from a  $100 \text{ mM}$  ethanolic stock solution 30–60 minutes prior to use, followed by gentle agitation and returning it to the incubator until needed. Dosages were increased to  $900 \mu\text{M}$  (or 0.9% ethanol vehicle) after four hours by additional spiking into apical Transwell compartments or device inlet reservoirs, making sure to empty out device tubing of lower-concentration media. Negative control microfluidics received similar treatment to ensure consistent disturbance of the cells from handling. At twenty hours,  $n = 2$  on-chip cultures additionally received  $900 \mu\text{M}$  capsaicinoids basally, and were changed again to positive control (10% ethanol) after 210–240 minutes.

### Permeability assay

Transwell TEER was measured with an EVOM2 instrument and STX2 chopstick electrodes (World Precision Instruments, Sarasota, Florida). Due to inadvertent media cross-contamination between two Transwells (negative control & vehicle), these are excluded from all permeability and metabolomic analysis.

For tracer dye permeability we relied on Lucifer yellow (Thermo Fisher L453) added to the media at  $1 \text{ mM}$  in the apical Transwell compartment or apical microfluidic channel inlet. To facilitate concentration equilibration in the basal



Transwell compartments, the cultures were placed on a rocking plate inside the incubator.

Basal Transwell compartment or basal microfluidic channel outlet samples of  $V_{\text{sample}} = 50 \mu\text{L}$  were collected at each timepoint  $n$ , transferred into a 96-well half-area flat bottom microplate, and measured using an Infinite 200 Pro fluorescence reader ( $\lambda_{\text{ex/em}} = 418/475 \text{ nm}$ ; Tecan, Männedorf, Switzerland). Serial dilution curves of reference (inlet) media were fitted with a Hill function to calculate fractional dye concentration  $C_{\text{out}}$  in basal (outlet) samples for each timepoint. Permeability in the devices was calculated as

$$P_{\text{app}} = \frac{C_{\text{out}}[1] \cdot \bar{Q}[\text{cm}^3 \text{ s}^{-1}]}{A[\text{cm}^2]}$$

where  $Q$  is the average volumetric flow rate, and  $A$  the permeable membrane area. For Transwells, the formula is more complex due to dye accumulation over time  $t$ . We moreover need to account for successive dilution from fresh media addition after each sampling step to keep the basal volume constant at  $V_{\text{basal}} = 800 \mu\text{L}$ .

$$\begin{aligned} P_{\text{app}}(n) &= \frac{V_{\text{basal}}[\text{cm}^3] \cdot \Delta C_{\text{out}}[1]}{A[\text{cm}^2] \cdot \Delta t[\text{s}]} \\ &= \frac{V_{\text{basal}}}{A} \cdot \frac{C_{\text{out}}(n) - \frac{V_{\text{basal}} - V_{\text{sample}}}{V_{\text{basal}}} C_{\text{out}}(n-1)}{t(n) - t(n-1)} \end{aligned}$$

### Immunostaining

For Transwells, media was aspirated and cells washed with PBS. Cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature. *Caution: paraformaldehyde may cause cancer and is suspected of causing genetic defects. Handle with care and proper protective equipment in a properly vented environment.* After three washes with PBS, 50  $\mu\text{L}$  blocking buffer (10% goat serum (Merck G9023) and 0.1% Triton X-100 in PBS) was added to each well and left to incubate for one hour at room temperature on a rocking plate. Subsequently, we washed once with PBS and added 50  $\mu\text{L}$  primary antibody solution in each well. This solution (10% blocking buffer in PBS) contained mouse anti-ZO1 antibody (Invitrogen 33-9100) at 2.5  $\mu\text{g mL}^{-1}$  and was left in the wells overnight at 4 °C. The next day, after two PBS washes, we added 50  $\mu\text{L}$  secondary antibody solution containing 10  $\mu\text{g mL}^{-1}$  goat anti-rabbit CF594 (Sigma SAB4600107) and left this to incubate one hour at room temperature. Finally, after two PBS washes, we added 50  $\mu\text{L}$  of the final counterstaining solution and incubated for 30 minutes at room temperature. This solution (10% blocking buffer in PBS) contained 4  $\mu\text{M}$  Hoechst 33342 (Invitrogen H3570) and 6.6  $\mu\text{M}$  phalloidin AF488 (Invitrogen A12379). Devices were washed three times with PBS and stored in the dark at 4 °C until imaging. Prior to imaging, we excised the Transwell membranes using a scalpel and mounted them using Vectashield antifade mounting medium (Vector Labs H-1000) between glass slides.

Device immunostaining proceeded with the same solutions and incubation times. Solutions were aspirated using the pump, and for incubations <1 h agitated by intermittent flow. Washing was replaced with ~10 minutes PBS perfusion for each wash step.

### Imaging

We acquired widefield fluorescent images of all  $N = 8$  tape microfluidic channels and  $N = 12$  Transwells. Additionally, we selected  $n = 2$  spots per device and  $n = 1$  spot per Transwell for confocal imaging. Spots were chosen near either end of the devices along the centerline, and near the center of the Transwells. We avoided areas with obvious imaging impediments (e.g. the fibers evident in Fig. 3), but otherwise made no attempts to optimize frame selection. For Fig. 3D and E, we selected one alternating-end spot per condition, and one representative image from the Transwells.

We relied on Fiji for all image analysis.<sup>13</sup> Confocal images were de-noised with the CANDLE algorithm,<sup>14</sup> and corrected for  $xy$ -plane tilt using TransformJ. Maximum intensity projections were calculated along  $x$ -,  $y$ -, and  $z$ -axes. In our microfluidic devices, the membrane (and its pores) yielded a signal comparable to that from cellular structures, likely due to inefficient blocking prior to antibody introduction. The  $z$ -projection calculations thus exclude the relevant  $z$ -slices. All fluorescent images were processed with CLAHE to emphasize local structural differences over longer-distance intensity variations which at least in part arise from staining variations within and across the microfluidic channels.

To estimate layer thickness, we applied auto-threshold segmentation to the  $x$ - and  $y$ -axis projections. The extracted thickness histogram was fitted with a log-normal distribution. For correlation analysis, we relied on the Coloc plugin to extract Pearson's  $R$  and related measures.

### Mass spectrometry analysis

Samples for metabolomic analysis were collected by freezing down permeability assay samples immediately after fluorescence measurement, and storing them at -80 °C. A total of  $N = 73$  samples were selected for analysis, encompassing timepoints 0 h, 4 h, 6 h, and endpoint for devices, and timepoints 4 h and endpoint for Transwells. The selection favored later timepoints to increase metabolite accumulation, but excluded Transwell timepoints where cell death was inferred for the higher capsaicinoid dosage (see Results section). Additionally,  $N = 11$  samples from device inlets or the no-cell Transwell were included at various timepoints (including also fresh media, and a freshly-prepared dilution series of capsaicinoids to estimate dosage).  $N = 11$  quality control samples were prepared by pooling aliquots from the 73 assay samples. The dual-polarity LC-MS on an Orbitrap ID-X (Thermo Fisher) coupled to a ZIC-PHILIC column (2.1 × 150 mm, 5  $\mu\text{m}$ ; Millipore, Billerica, MA) was performed as previously described.<sup>15</sup>



The raw data were converted into an open-source format using ProteoWizard.<sup>16</sup> We employed XCMS online for feature alignment,<sup>17</sup> with parameters derived from quality control samples using IPO.<sup>18</sup> The data and XCMS analysis are available online.<sup>19</sup> This pipeline yielded ~18 000 features. Drift compensation was performed with statTarget based on the quality control samples (QC-RFSC algorithm), after filling missing features using half-minimum estimation (within-group 70% rule).<sup>20</sup> We further discarded features with remaining quality control RSD > 40%. Lastly, we manually filtered out features associated with capsaicinoids themselves. We relied on a combination of the following criteria: known isotopes/adducts of capsaicinoids; grouping classification by XCMS CAMERA; increasing feature intensity with concentration in the capsaicinoid pseudo-calibration samples; and >5-fold feature intensity in capsaicinoid references over regular media controls. This left us with ~12 500 features for analysis. Univariate and multivariate analysis were performed with statTarget (data were generalized log-transformed and mean-centered). The between-groups FDR-corrected *p*-values and associated fold-changes were used as the inputs for network analysis. Therein we relied on MetaboAnalyst, specifically its combined mummichog (*p* < 0.1 cutoff) + GSEA approach using the MTF metabolomic model (5 ppm mass accuracy).<sup>21</sup> We discovered that the GSEA component of this analysis pipeline proved unstable upon repeat analysis. Therefore, we combined GSEA *p*-values and NES scores from 9 analysis runs by geometric<sup>22</sup> and arithmetic averaging, respectively, before integrating this with the mummichog results through Fisher's method as intended by the authors.<sup>23</sup>

## Results & discussion

### Device construction

Our microphysiological system, displayed in Fig. 1, features 8 independent “organs”, each with two channels (1.5 × 0.2 mm<sup>2</sup> cross-section) vertically separated by a track-etched membrane. The permeable area of 19 ± 1 mm<sup>2</sup> accounts for a ~80% majority of the total cell growth area, important for permeability assays and potential co-culture applications. We construct it solely from tape and polycarbonate (PC) – a plastic well-established as non-cytotoxic, hydrophilic (albeit weakly), and with good tape-bonding characteristics. While the lateral channel geometry can be freely designed with CAD, the channel height is defined by the thickness of the tape. With a tape lamination approach, we can achieve reasonable flexibility also in this dimension.

The off-the-shelf PC connector plate accounts for three-quarters of the materials cost budget of our devices. It offers a key advantage over *e.g.* Kratz *et al.*'s use of manually drilled glass slides,<sup>11</sup> however, with a simple chip-to-world interface for elastic tubing (one of the most critical, but also most often overlooked considerations in academic microfluidics). The microscopy slide format also affords simple imaging with existing equipment. For manual assembly, we rely on

blunt needle guideposts to provide self-alignment of all layers from the top down, which provides a comparatively rapid and simple process compared to single-“organ” device designs.

### Material & fabrication evaluation

Regarding the tapes, we selected two medical-grade candidates for evaluation – synthetic rubber adhesive-based 3M 9877, and acrylic adhesive-based 3M 9889. They were selected based on high adhesive strength and manufacturer-supplied reports on ISO 10993-compliant cytotoxicity testing (*cf.* Table 2). They exhibit excellent adhesion to PC (employed here) as well as PET, another common material for track-etched membranes. Compatibility with more specialized materials would require case-by-case evaluation wherein consideration of respective advantages and disadvantages may ultimately point to different tape selection than here (or prove incompatible with our process). For PDMS membranes,<sup>24</sup> for instance, silicone adhesive-based tapes would likely prove more suitable; Si-based membranes,<sup>25</sup> on the other hand, generally adhere well to the 3M tapes, but due to brittleness may not survive the assembly process.

We considered patterning these tapes with either a vinyl cutter (cost from €100) or a CO<sub>2</sub> laser cutter (from €300). At the lower end of these price ranges – which is where our approach is aimed at – either method will still provide minimum feature sizes in the 0.5–1 mm range at an accuracy of ~0.1 mm. This is already sufficient for the relatively large-




Fig. 1 (top) Photograph of assembled device (with intentional top/bottom channel offset for better visualization) perfused with colored solutions. (bottom) Schematic showing device layer structure.



scale structures of barrier-on-chip microfluidics, so the improved figures of merit of more advanced equipment (such as those in our own facilities) are less relevant. The main difference of note between the methods lies rather in the constraints of a physical blade (~1 mm length) inserted into the – in our case, tacky – substrate for the knife cutter; this works well for straight or slightly curved cuts (ESI† Fig. S1), but handles tight bends (<0.5 mm) and sharp corners poorly.

The more important consideration, however, is compatibility with the biological elements – in our case, Caco-2/BBe1 epithelial cells (a clone of Caco-2 colorectal adenocarcinoma). Caco-2 cells are a common barrier model system, but the line is known to be heterogenous, contributing to significant variation between sources/labs as different sub-populations gain dominance over many passages.<sup>26</sup> Clonal lines avoid this particular source of variability, with BBe1 in particular having been selected for Brush Border expression.<sup>27</sup> This clone is readily available, known for reproducible barrier formation, and widely used in gut-on-chip applications.<sup>28,29</sup>

In Fig. 2, we consider cell coverage after 8 days of culture either directly on top of or adjacent to the two tape candidates, processed with either of the two methods under consideration. We chose to assess coverage rather than viability to eliminate potential interference from loss of dyes for metabolic activity (alamarBlue or similar) to the tape surfaces. We observed the highest coverage (interquartile range (IQR): 98 to 99%) for knife-processed 9877 tape. The acrylic-based 9889 tape shows somewhat more variable growth and/or survival (IQR: 71 to 93%). Laser processing appears to induce generation of cytotoxic compounds especially in the rubber-based 9877 tape, reducing cell coverage by half (95% confidence interval (CI): -20 to -80%) both on and next to the tape.

Kratz *et al.*, by way of comparison, mainly consider knife-cut ARcare tapes based on acrylic adhesives (akin to 3M 9889). Their cell coverage assessment is qualitatively similar to what we observe with 3M 9877 (rather than the similarly acrylic-based 9889). It may be that ARcare's acrylics are more suitable for cell contact than the 3M version. However, the different cell type (BeWo b30) and study duration (48 h) allows for alternative explanations. Their study did not entail any synthetic rubber-based tapes (akin to 3M 9877).

Another important consideration for microphysiological system construction is the ability to sterilize – or at least disinfect – the materials. The 3M 9877 tape offers an additional advantage in this regard, since it is autoclavable (both 9889 and 9877 can be EtO or gamma-sterilized; we note that ARcare does not provide any relevant information for their tapes). For our assembled systems, however, we relied on low-resource disinfection by perfusion with 70% ethanol. The adhesive of both tapes withstands such perfusion for at least 15 minutes, and no leakage was observed over 14+ days of perfusion with aqueous solution.


Overall, our initial assessment establishes knife-cut 3M 9877 as a good candidate for organ-on-chip construction

based on lack of obvious cytotoxicity as well as its fabrication properties. Our subsequent barrier-on-chip study with Caco-2/BBe1 epithelial cells suggests that it is indeed suitable for such applications.

### Biological validation & effects of membrane pore size


**Imaging.** We first assess cellular coverage and morphology with fluorescent imaging. This is obtained after 8 days of Caco-2/BBe1 cell culture, followed by the 24 h capsaicinoid study described in the second part of this paper. In the present section, we will largely limit our analysis to comparisons between the Transwells and tape devices (Fig. 3A) that were cultured in parallel. In the widefield images, we observe consistent and complete coverage of all microfluidic channels (Fig. 3B) and Transwells (Fig. 3C) with epithelial barriers, except for those intentionally disrupted. Some heterogeneity in barrier morphology is apparent between channels as well as locally within channels. This type of variability is however in line with that exhibited in the Transwells, and is common with any gut epithelial cell culture (even Caco-2/BBe1).<sup>28,30–32</sup> The intensity variations are moreover partly caused by differing staining efficiency – as with any organs-on-chips, the multiple wash steps in immunocytochemistry present the biggest opportunity for bubble introduction in the overall workflow.

To better compare structural features, the widefield imaging is supplemented by confocal imaging. This reveals significant differences in barrier morphology. Qualitatively, we see more pronounced undulations of the epithelial cell layer in the devices (Fig. 3E; *y*-projections) compared to flatter layers in Transwells (Fig. 3D). In the latter, the cell layer is however overall thicker at an average 49  $\mu\text{m}$  (IQR: 47 to 51  $\mu\text{m}$ ) compared to 33  $\mu\text{m}$  (IQR: 30 to 36  $\mu\text{m}$ ) inside the device channels. Similarly, average cell footprint decreases from 22  $\mu\text{m}$  (95% CI: 21 to 23  $\mu\text{m}$ ) diameter to 16  $\mu\text{m}$  (95% CI: 14 to 17  $\mu\text{m}$ ) diameter. Thus, cells have similarly columnar shapes



**Fig. 2** Cell coverage of Caco-2/BBe1 cells after 8 days of culture inside a 24-well plate. Well bottoms ( $N = 8$ ) were 50% covered by tape of the type and processing mode given. Cell coverage was assessed both on top of the tape (crosses) and in the non-covered well area next to the plate (circles).





**Fig. 3** Immunocytochemistry fluorescence micrographs. (A) Overview of the experimental conditions. (B and C) Widefield images (scale bars: 500  $\mu\text{m}$ ) respectively illustrating intact epithelial layers across tape chips ( $\Theta$  and  $\odot$  conditions,  $n = 6$ ; complete disruption for  $\oplus$ ,  $n = 2$ ) and Transwells ( $\Theta$  condition,  $n = 8$ ; complete disruption for  $\odot$ ,  $n = 4$ ). The fibers are fabrication artifacts. (D and E) Selected maximum intensity confocal projections (scale bars: 50  $\mu\text{m}$ ) along  $z$ - and  $y$ -axes corresponding to the areas indicated with white boxes in (B and C) for Transwells ( $\Theta$  condition;  $\odot$  was only widefield-imaged due to low survival) and devices ( $\Theta$  and  $\odot$  conditions;  $\oplus$  was only widefield-imaged due to low survival). The top surface of the track-etched membrane is indicated with a dotted white line. The white arrows indicate features discussed in the text.

in both formats, but are smaller in volume inside our microfluidic channels. It is worth noting here that all the other conditions studied (membrane pore size, capsaicinoids) are associated with well-overlapping morphological IQRs/CIs.

Our observations on cell morphology in devices compared to Transwells are partially in contrast with other works demonstrating thicker epithelial layers in microfluidic culture.<sup>29,32</sup> This may be due to three factors. First, unlike some advanced PDMS-based systems, our tape-based approach cannot supply peristalsis-like lateral strain. This is implicated in some aspects of epithelial differentiation, though the extent of its impact remains a matter of

debate.<sup>24,28,33</sup> Second, we relied on media recirculation to limit media consumption during maturation (d2–7). However, Shin *et al.* recently found that basally excreted factors in polarized Caco-2/BBE1 layers can inhibit 3D morphogenesis.<sup>29</sup> In a recirculated system the situation is thus more akin to Transwells, with these factors continuing to reside in the media. Last but not least, our microfluidic channels provide less physical growth height ( $\sim 200 \mu\text{m}$ ) than some other systems, which has been shown to limit epithelial barrier thickness.<sup>29</sup> The reduced height allows for more even shear distribution (given typical 1–2 mm channel width), in our case an average of 2.5 mPa (pulsatile; 15 mPa peak). We



note that our epithelial thickness is comparable to other works with similar culture duration, channel height, and shear.<sup>28</sup>

Immunocytochemistry reveals one critical difference of biological relevance between static and dynamic culture. In Transwells (Fig. 3D, white arrows in *y*-axis projection), both actin and even more so tight junction protein 1 (ZO1) are almost exclusively confined to the membrane-side. This indicates a lack of (or even inverse) polarization (we will continue to refer to the above-membrane compartment as “apical” in both Transwells and devices for consistency). Microfluidic culture (Fig. 3E), on the other hand, shows clear actin expression both basally (membrane adhesion) and apically, where we also observe ZO1 expression. Besides this much-improved polarization in microfluidic culture, tight junction expression is moreover qualitatively more consistent and defined compared to Transwells (*z*-projections; independent of subsequent capsaicinoid treatment). This is indicative of shear stress in the optimal regime for Caco-2/BBe1 barrier formation.<sup>28</sup>

**Tracer permeability.** We assess epithelial barrier integrity using Lucifer yellow (LY) fluorescent dye diffusion. Fig. 4 shows that strong barriers have formed by this point in all channels, with apparent permeability coefficients  $P_{app}$  decreasing by over two orders of magnitude compared to membrane-only controls. After accounting for outliers due to bubbles (asterisk) and those below the assay noise limit, we measure a  $P_{app}$  of  $0.95 \text{ nm s}^{-1}$  (95% CI: 0.67 to 1.33; averaged over both  $1 \mu\text{m}$  and  $0.4 \mu\text{m}$  membrane pore size) in our tape

devices. This is well within the confidence interval of that from Transwells at  $0.65 \text{ nm s}^{-1}$  (95% CI: 0.23 to 1.86;  $0.4 \mu\text{m}$  pore size, but at ~2-fold higher density compared to device membranes). The lower variation within devices compared to Transwells is worth emphasizing, indicating good reproducibility both in device fabrication as well as in barrier formation. Our measured  $P_{app}$  also agree with LY literature values for Transwells (Caco-2;  $1\text{--}7 \text{ nm s}^{-1}$ )<sup>34,35</sup> or an on-chip model (Caco-2/BBe1:HT29-MTX 9:1 co-culture;  $1.2 \text{ nm s}^{-1}$ ).<sup>36</sup> While not employing LY, a number of studies have shown similar or even increased  $P_{app}$  in microfluidic culture compared to Transwells, matching the trends we observe.<sup>24,32</sup>

For on-chip culture, we consider whether barrier integrity is dependent on the pore size ( $0.4 \mu\text{m}$  or  $1 \mu\text{m}$  diameter) of the track-etched membranes used. We measure an increase in barrier function with decreasing pore size, as  $P_{app}$  decreases by  $\sim 0.23$  orders of magnitude (95% CI:  $-0.46$  to  $+0.01 \log_{10}$ ) going from  $1 \mu\text{m}$  to  $0.4 \mu\text{m}$  pores. While not previously studied with Caco-2, this aligns favorably with a  $\sim 0.35 \log_{10}$  decrease reported for mouse brain endothelial cells in Transwells.<sup>37</sup> Additional Transwell data have been published for human brain endothelium, with mixed trends.<sup>25,38</sup> The study showing higher  $P_{app}$  with  $0.4 \mu\text{m}$  over  $1 \mu\text{m}$  pores is however confounded by a 2-fold difference in membrane pore densities.

Lastly, we compare measured  $P_{app}$  values with theoretical ones calculated following the model by Bittermann and Goss.<sup>39</sup> For membrane-only controls, the model consistently underestimates  $P_{app}$  by  $\sim 40\%$ , likely due to errant assumptions about LY diffusion through pores. In the presence of the epithelial barrier (the focus of their work), the model prediction is conversely 3–5× higher than observed values. This is still within the bounds of the predictive power of the model ( $\pm 0.48 \log_{10}$ ), and in line with most of the – like LY<sup>40</sup> – fully ionized species considered in their paper.

**Metabolomics.** Untargeted-omics approaches provide a wealth of biological information. We apply a metabolomics approach to our on-chip and Transwell small-intestine models to gain insight into biological function across conditions. The single-order LC/MS on sampled (for devices, effluent) media captures changes in small ( $<1 \text{ kDa}$ ) molecules secreted (and consumed) by the cells. Our study design focuses on global rather than specific changes, *i.e.* considering multivariate and network analysis rather than annotation and validation of a small subset of compounds.

Here, we first take a look at the overall principal component analysis (PCA) across all collected data (Fig. 5A). Within two principal components accounting for almost 40% of the overall variation, the unguided clustering proves insightful. PC1 distinguishes well between apical (closed symbols; more positive) and basal (open symbols; more negative) compartments in either culture system. This indicates a sizable conservation in biological function between Transwells and microfluidics. PC2, on the other hand, captures the type of experiment as well as the later-described capsaicinoid condition. Devices (circles) generally





Fig. 4 Fluorescent tracer LY permeability compared between Transwells (TW, black) and tape devices featuring either  $1 \mu\text{m}$  (orange;  $n = 4$ ) or  $0.4 \mu\text{m}$  (purple;  $n = 4$ ) pore size membranes. We plot data both without cells (left) and after 8 (TW;  $n = 6$ ) to 9 (on-chip;  $n = 3\text{--}4$ ) days of epithelial cell culture. The noise limit for the assay is indicated in gray, higher for TWs due to the less favorable ratio of permeable surface area to basal volume. The starred device datum represents an outlier likely due to a bubble in the channel ( $P_{app}$  for this device at subsequent timepoints is in line with others). Theoretical predictions for permeability are shown in green.<sup>39</sup> The reference derives an error range by comparing their cell layer model to experimental data for ~150 compounds (the “no cell” condition does not receive similar attention and is not calculated with an error range).





**Fig. 5** (A) Overall PCA of metabolomic data. Samples are grouped by culture type (circles vs. triangles), apical/basal sampling compartment (closed vs. open), and capsaicinoid application (red vs. blue). “Blank” media sampled throughout the experiment is also included (green crosses; capsaicinoid media additionally features a red dot). (B) Sub-group PCA showing the effect of permeable support pore size (purple vs. orange;  $N = 4$  devices each) in our devices. One apical (1  $\mu$ m) datum is missing due to a sampling issue.

score negative, and Transwells (triangles) positive, while capsaicinoid application (red) in either system shows a trend of PC2 towards zero compared to the respective controls (blue). The described patterns are clearest for apical compartments, whereas basal compartments show more overlap between conditions and also with the no-cell media controls. Since basal compartments require permeation of compounds across the membrane, the lower response and closer resemblance to media is expected. Higher-order PCs (ESI† Fig. S2) show additional differentiation between capsaicinoid and culture type conditions, discussed at a more granular level in the second half of the paper. The remaining variation among samples is largely due to culture time (causing degradation of compounds in inlet and outlet reservoirs, with additional accumulation effects in Transwells), which is partially reflected in the spread of the media control PCA (green crosses).

Metabolomic analysis also reveals the clearest differences based on membrane pore size amongst our assays. While not

apparent in the full data (Fig. 5A), PCA on the relevant subset (Fig. 5B) shows distinct clusters. Apical *versus* basal sampling again accounts for the bulk of sample variation (PC1). PC2 however differentiates between 0.4  $\mu$ m diameter pores (purple; more positive) and 1  $\mu$ m diameter pores (orange; more negative).

Network analysis is more suited for comparisons within the same “organism”, or in our case, culture system. The differing assay kinetics between Transwells (accumulating, and significantly diluting in the basal compartment) compared to devices (continuous perfusion with matched apical & basal volumes) caution against direct comparisons in network activity. One observation that we would like to mention regardless is that Cytochrome P450 activity is among the higher-scoring pathways (when comparing sampled media to blanks) in both Transwells (38 significant metabolites, out of 52 possible within the pathway) and devices (50 significant hits). The extent of this particular pathway in Caco-2 cells is an occasional matter of debate.<sup>41</sup> Our study supports a relatively robust presence in both Transwell and device culture after 8 days, though the nature of our study does not allow for distinguishing enzyme isoforms.

The different membrane pore sizes present a better application for network analysis. While ensemble differences appear in the PCA (Fig. 5B), the network analysis does not show any significantly affected pathways ( $p < 0.1$  cutoff). While differences between pore size are thus present, they appear to be quite subtle, in line also with our other assay results.

### The effects of chili pepper (capsaicinoids)

The above section demonstrates epithelial barrier formation in our tape-based microphysiological systems. We studied the impact of membrane pore size on the cells, and compared our devices to traditional Transwell culture on a number of metrics. To additionally evaluate stimulus response, we select a common food compound: capsaicinoids, the “active ingredient” in chili peppers. They are of potential pharmaceutical interest for pain and body weight management, or cancer treatment.<sup>42</sup> Previous *in vitro* studies on epithelial barriers have focused mainly on short-term (1–2 hours) cellular response, for a dose range of 100  $\mu$ M to 500  $\mu$ M capsaicin.<sup>43–52</sup> While no studies employed Caco-2/BBE1 specifically, qualitative comparisons remain useful with Caco-2 barriers in particular, but also for other lines. These studies have established actin reorganization linked to tight junction opening, and explored the cellular pathways behind it.

**Capsaicinoid concentration.** For our study, we select two nominal apical capsaicinoid levels: 600  $\mu$ M (the focus for Transwells) and 900  $\mu$ M (the focus for devices) – the rough equivalent of eating (and efficiently digesting) a very hot habanero chili pepper on an empty stomach.<sup>53,54</sup> While the untargeted single-level LC/MS does not allow for quantification, it does allow us to infer approximate (order-



of-magnitude) relations between nominal and effective concentrations. Due to the qualitative nature of this analysis, we will however continue to refer to nominal doses throughout the subsequent sections.


From both Transwell and device data, we can infer an apparent permeability on the order of  $100 \text{ nm s}^{-1}$  for capsaicinoids. In media controls sampled after 20 h of incubation, concentrations are reduced by approximately  $-0.5 \log_{10}$  (capsaicin),  $-1 \log_{10}$  (dihydrocapsaicin), and  $-2 \log_{10}$  (nordihydrocapsaicin). This suggests loss from precipitation (capsaicinoids are poorly soluble in water) and/or slow thermal breakdown.<sup>55</sup> We find that concentrations sampled from devices are an additional  $-0.5 \log_{10}$  decreased compared to the media control. We attribute this loss to the microfluidic tubing, which makes up for  $\sim 93\%$  of the fluidic surface area. While PDMS can soak up significant quantities of hydrophobic compounds, this is a bulk phenomenon not applicable to our devices, making the tape microfluidics themselves ( $\sim 6\%$  surface area) the more unlikely candidate.<sup>56</sup> We note that none of the referenced studies on capsaicinoid effects<sup>43–52</sup> have investigated whether effective concentrations match nominal ones (and in some studies, it remains unclear whether dosing was apical, basal, or global).

Overall, the implications are (1) a rapid apical/basal equilibration in Transwells over short ( $<4$  h) timescales, which we recapitulate in two of our microfluidic channels over the final experimental hours by combined apical and basal dosing; and (2) a lower effective dose in devices, which we seek to compensate for by increasing nominal dose compared to Transwells to the maximum indicated by capsaicinoid solubility and by keeping ethanol vehicle concentration  $<1\%$ . Our lowered effective doses in devices roughly correspond to eating a habanero chili pepper on a full stomach.<sup>53,54</sup>

**Ethanol vehicle.** To rule out effects from ethanol as the vehicle for capsaicinoids, we evaluate Transwells with regular media compared to those spiked with equivalent amounts (0.6% to 0.9%) of ethanol as in the parallel capsaicinoid treatment. These effects prove to be negligible in all analyses. No qualitative morphological differences are observed in imaging. In quantitative TEER and permeability, the group differences score  $p > 0.7$  and  $p > 0.5$ , respectively. In the metabolomic analysis, at most 1 compound scored  $p < 0.05$ , compared to  $\geq 50$  compounds for all other comparisons. We thus treat ethanol vehicle as equivalent to negative controls in subsequent analysis.

**Permeability.** Over the initial four hours of the experiment, we apply a nominal dose of  $600 \mu\text{M}$  capsaicinoids in the apical compartments. Considering first Transwell TEER (Fig. 6A), we observe a slight drop after 30 minutes independent of treatment, indicating simply disturbance of the barrier form the media change. In the subsequent hour, the barrier recovers, with capsaicinoid-treated epithelial layers interestingly showing 30% higher barrier function (95% CI: +5 to +56%) before reverting closer to the controls again by 4 hours. This sinusoidal full-period

timeline differs from some reports of a “half-period” reversible drop in TEER.<sup>47,50</sup> A post-exposure TEER increase has been observed with MDCK (a canine kidney epithelial line) – albeit at different timescales – as well as at least once in Caco-2 barriers.<sup>46,50,51</sup> Compared to these studies, our sampling intervals may miss out on a larger initial drop due to an overall compressed or expanded time course. More relevantly, the type of “full-period” TEER response we observe



**Fig. 6** Permeability assays with capsaicinoid application. We compare negative controls (blue) to capsaicinoids at nominal apical concentrations of  $600 \mu\text{M}$  (yellow) and  $900 \mu\text{M}$  (red), as well as a no-cell control (dotted green). (A) Transwell TEER ( $N = 12$ ), with shaded areas tracing the 95% confidence interval. (B) Apparent LY tracer permeability in Transwells, with the assay noise limit indicated by the shaded gray area. Unlike TEER, the permeability assay collects an average over the sampling period, indicated by the length of the lines. (C) Analogous LY tracer assay in microfluidic devices ( $N = 8$ ), with added conditions of global nominal  $900 \mu\text{M}$  capsaicinoids (dotted yellow;  $n = 2$ ) and positive control (dotted purple; 10% ethanol;  $n = 2$ ).



has also been reported for natural chili pepper extract on HCT-8 cells (a gut epithelial line like Caco-2).<sup>43</sup> The capsaicinoid mixture in our study is likely more reflective of chili pepper extract than pure capsaicin, though in previous publications the purity of the capsaicin is not always denoted.

Comparing the TEER now to LY permeability in the Transwells (Fig. 6B),  $P_{app}$  similarly shows the negative controls recovering from initial higher values due to the media change disturbance by 2–4 hours. Unlike TEER, capsaicinoid-treated epithelial barriers exhibit consistently worse barrier function in this assay by one order of magnitude (95% CI: +0.5 to +1.6  $\log_{10}$ ). These opposing trends between assays are intriguing (and were similarly observed in an independent Transwell experiment; ESI† Fig. S3). None of the previously published studies on capsaicin have considered small-molecule tracers alongside TEER. Although LY is generally accepted as a good marker of paracellular permeability, its correlation with gold-standard [<sup>3</sup>H]mannitol is not perfect.<sup>57</sup> Neither is the correlation of TEER with either of these tracer's  $P_{app}$ . Most intuitive explanations for mismatch apply to a weaker barrier indicated by TEER compared to tracers, due to TEER's reliance on smaller ions and its relative sensitivity to localized disruption.<sup>58</sup> The case we observe here is more likely to involve transcellular transport. This mode of transport can play a role at TEER values  $\gtrsim 250 \Omega \text{ cm}^2$  if the relevant pores are open at the same time, and can affect  $P_{app}$  overall.<sup>58</sup> This reasoning would suggest that capsaicinoids can decrease synchronized opening of transcellular ion pores, and/or relatively increase transcellular transport of LY.

By contrast, a subsequent dose increase to 900  $\mu\text{M}$  (4 h until endpoint) causes Transwell permeability to increase by both measures (Fig. 6A and B). The first 2–3 hours after application already see marked changes, with TEER decreasing by 65% (95% CI: 53 to 76%) and  $P_{app}$  increasing by 1.8 orders of magnitude (95% CI: +1.3 to +2.3  $\log_{10}$ ). Unlike the lower-dose effect, this proves irreversible, and both permeability markers approach no-cell values by the next-day experimental endpoint. The initial rapid decrease, and the loss of viability, are consistent with observations of  $>750 \mu\text{M}$  capsaicin (apical) or  $>300 \mu\text{M}$  (global) in MDCK.<sup>50,51</sup>

While the Transwell behavior – in particular the differences observed between TEER and permeability – is intriguing, the comparison of largest interest to our current study is with tape microfluidic culture (Fig. 6C). Here we can only rely on tracer permeability, since a low-cost platform and setup precludes addition of TEER electrodes. As with Transwells, we observe fluctuations even with the negative controls. While the disturbance of cells is less direct than in Transwells, movement of the barriers-on-chips setup in and out of the incubator tends to have larger effects due to lower media volumes (and thus heat retention).

At first glance, the device response in  $P_{app}$  over time is less pronounced than from the Transwells (Fig. 6C vs. B). This is

in line with expectations due to the different nominal *versus* effective concentrations in the respective systems, as discussed at the start of this section. Nominally, however, the time course mirrors that of the Transwells, at 600  $\mu\text{M}$  apically for the first four hours, and 900  $\mu\text{M}$  thereafter (two on-chip barriers additionally receive 900  $\mu\text{M}$  capsaicinoids basally for the last four hours prior to endpoint). One qualitatively obvious change is when – to assess the validity of the device  $P_{app}$  assay – we disrupt two “organs” with a cytotoxic dose of ethanol (positive control; 10% apical & basal). This yields an order of magnitude increase in  $P_{app}$  within the first hour (subsequent readings vary significantly due to dead cells clogging the tubing as verified by visual inspection).

For capsaicinoid application overall, a two-way repeated-measures ANOVA supports a small shift in  $P_{app}$  either way (95% CI: -0.21 to +0.10  $\log_{10}$ ) compared to controls. The nominal decrease by -0.06 orders of magnitude appears largely independent of dose, with no sizeable effect even by combined apical and basal capsaicinoid application (900  $\mu\text{M}$ ). This stands in contrast to the clear +1.0  $\log_{10}$  increase in  $P_{app}$  over controls for Transwells at comparable effective dosage and application time (the very initial four hours of the experiment). We suggest two hypotheses. First, the lack of response in microfluidic culture could be due to desensitization from the prior lower dosage. Alternatively, the Transwell culture may overall be more sensitive to capsaicinoid-induced barrier alterations. As observed earlier (*cf.* Biological validation, Imaging subsection), the microfluidic culture exhibits more *in vivo*-like polarization and junction definition. Characteristic of growth under shear stress, this is likely to translate also into altered cellular response. Indeed, reduced epithelial toxicity on-chip has been observed *e.g.* with gentamicin action on MDCK.<sup>59</sup> It is worth noting that *in vivo* experiments report nominal capsaicinoid concentrations 5–10 times higher than what we observed as cytotoxic in Transwell culture, with minimal adverse effects.<sup>60,61</sup>

**Imaging.** Widefield imaging (Fig. 3C) reveals nearly complete cell death after the full capsaicinoid time course in the Transwells, in line with the observed TEER and  $P_{app}$  values. For the devices (Fig. 3B), however, the only qualitatively obvious condition is again the cytotoxic dose of ethanol resulting in complete cell death. To discern differences between capsaicinoid and control conditions in the tape microfluidics, we need to consider the confocal images (Fig. 3D). Qualitative inspection reveals somewhat less well-defined tight junction expression after capsaicinoid application. We further observe increased actin localization at multi-cell junction points (white arrows). This has been reported for both Caco-2 and MDCK upon capsaicin application.<sup>48,50</sup> The localization is not as common here as in those studies, but ours consider a much longer time course (24 h *vs.* 6 h). On such timescales, other studies have shown an actin expression profile that mirrors TEER, decreasing initially before increasing significantly over controls.<sup>45,46</sup> This



likely results in less organized F-actin repolymerization masking most of the triple-junction localization by 24 h.


Quantitative analysis further substantiates alterations in cellular junctions, with actin/ZO1 colocalization decreasing in terms of Pearson's  $R$  from 0.53 (controls) by  $-0.13$  (95% CI:  $-0.27$  to  $+0.01$ ). This trend is conserved for other correlation measures. A similar analysis grouped by membrane pore size, conversely, shows a negligible change in correlation of  $-0.02$  (95% CI:  $-0.18$  to  $0.14$ ). Such colocalization analysis is more robust than direct comparisons of fluorescence intensity. The change in colocalization implies a reorganization of the actin network and/or the cellular tight junctions, in line with our qualitative analysis conclusions.

## Metabolomics

Our focus for metabolomic analysis is the  $600\text{ }\mu\text{M}$  nominal dose for Transwells, and a  $900\text{ }\mu\text{M}$  nominal dose for devices. As discussed earlier, this provides us with a comparison of more closely similar effective dosage between culture systems. As also briefly mentioned earlier, PCA of the overall dataset (Fig. 5A & ESI† Fig. S2) shows grouping according to capsaicinoid application compared to negative controls. The trends (PC2 toward zero, PC3 & PC4 more positive) are conserved between Transwells and our tape-based devices, and indeed differences between culture types disappear in the first two PCA components. This suggests capsaicinoid effects dominate over culture type differences, and that biological response is overall quite similar between Transwells and our tape-based barriers-on-chips.

For further insight, we turn to metabolic network analysis (Fig. 7). This reveals significant impact of capsaicinoids on the metabolic pathways of our epithelial barriers. Considering first overall changes (Fig. 7A), the devices show much more extensive metabolic changes compared to Transwells. We believe this is in part due to dilution effects making detection in the basal Transwell compartment more challenging. However, the two pathways with  $p < 0.05$  in Transwells are mirrored in devices ( $p < 0.1$ ). Two additional high-scoring pathways ( $p < 0.05$ ) in devices are further mirrored by the Transwells ( $p < 0.1$ ). Biological responses are thus correlated between culture systems not only in PCA, but also on the network level.

Before considering the specific networks affected, we quantify the correlation in terms of the normalized enrichment (NES) of pathways between Transwells and devices at the various timepoints (Fig. 7B). This reveals Transwell (basal) response as "most similar" to devices' basal compartment at the 6 h timepoint (Pearson's  $R = 0.53$ ; topmost row/leftmost column). Based on effective dosages, we would have expected higher similarity at the 24 h timepoint. However, it appears that – in spite of rapid capsaicinoid equilibration in Transwells, and the cells' weak polarization compared to devices – the Transwell metabolic response remains "polarized". This matches the conserved grouping along PC1 in PCA with capsaicinoid treatment (Fig. 5A). The two globally-dosed devices at 24 h, in contrast, show rather apical-like response also in the basal compartment (bottom row/rightmost column). Inherent cell layer polarization thus appears to be less critical for



**Fig. 7** Metabolomic network analysis of capsaicinoid effects (◎) on Transwells (TW) and microfluidic devices, separated by basal and apical sampling compartments. (A) The data illustrate significant changes in metabolic networks compared to negative controls (⊖) in terms of  $p$ -values (color scale from purple to cyan;  $p > 0.1$  is colored gray/white). Abbreviated network annotations from the MTF metabolic model are listed at the bottom; we have loosely added grouping at the top. The direction of the activity change (in terms of normalized enrichment score NES) is indicated by the overlaid plus/minus signs (missing overlays signify low NES). We include the top 20 pathways (as determined by  $p$ -values across conditions; smallest pathways  $<10$  hits excluded). For more closely matched effective dosage, Transwell data ( $n = 4$ ) is for a nominal dose of  $600\text{ }\mu\text{M}$  (4 h), device data ( $n = 6$ ) for a nominal dose of  $900\text{ }\mu\text{M}$  (pooled timepoints). (B) Pearson's  $R$  correlation matrix (color scale from anticorrelation in blue to co-correlation in red, with white signifying low correlation) for NES at the different timepoints (Transwells:  $n = 4$ ; devices:  $n = 6$ , except  $n = 2$  for 24 h/global dosing) and compartments as labeled on the top/side and bottom.



capsaicinoid response than its concentration gradient across the barrier.

The richest amount of information from our assay, however, is contained within the metabolic pathways affected in devices (Fig. 7A). We broadly group the pathways into “amino acid” metabolism, “carbohydrate” metabolism, and “others”. Tyrosine metabolism is one of the strongest hits overall and upregulated in every compartment and timepoint (including Transwells), while other identified amino acid pathways are downregulated. Most of these pathways are sizable and not straightforward to interpret. The tyrosine metabolism, for instance, involves dopamine and adrenaline. These are consistent with stress modulation as discussed later (for “other” pathways).<sup>62</sup> The literature also provides a more capsaicinoid-specific line of reasoning. Capsaicin happens to be a structural analog for tyrosine, and can compete with the amino acid in its tRNA aminoacylation.<sup>63</sup> This would leave excess tyrosine available for other cellular pathways, consistent with the increased tyrosine metabolism we observe.

Besides amino acid pathways, various networks involved in carbohydrate meta- and catabolism are indicated and generally upregulated. This appears to be in agreement with findings of increased energy metabolism in a range of *in vivo* studies.<sup>64</sup> For Caco-2 cells specifically, one prior study also describes increased energy metabolism along with overexpression of two particular enzymes involved in glycolysis.<sup>49</sup> Our network-level approach is less sensitive to changes in individual enzymes, but the glycolysis pathway involving these enzymes is present, and the other upregulated “carbohydrate” pathways identified are generally closely adjacent.

The “other” category groups a range of pathways not so easily categorized. It includes small-molecule pathways (pyruvate, biopterin, ...) which are closely intertwined with the energetic and stress responses of other networks. In terms of stress and inflammation, the retinol pathway deserves separate attention. Increases in gut retinoid metabolism have been documented for a number of stressors in rats.<sup>65,66</sup> Phosphatidylinositol phosphate is similarly indicated in stress response.<sup>67</sup> Even more relevantly, this pathway is closely linked to cytoskeletal reorganization, aligning well with our (and others', as discussed earlier) imaging results.

We are aware of one further study considering metabolic effects of capsaicinoids on Caco-2 barriers.<sup>52</sup> Rohm *et al.*, using a targeted (and thus more individually sensitive) approach find increased acetyl-coenzyme A synthetase activity, indicating higher fatty acid biosynthesis. For our untargeted assay, however, the overall number of compound hits within this pathway is comparatively low (<30% coverage; compared to  $\geq 50\%$  for the pathways we report on), providing a likely explanation for its absence in our analysis.

Overall, we thus find a complex metabolic response to capsaicinoids in our on-chip barriers that aligns with other *in vivo* and *in vitro* findings from literature. This high metabolic response – sustained through all timepoints (Fig. 7B) – combined with (compared to Transwells for

similar effective dose) much less pronounced changes in barrier integrity presents an argument against the desensitization hypothesis we offered in the earlier analysis (*cf.* permeability discussion). Instead, the response we observe in our devices may indeed reflect a more physiological-like response to chili peppers.

## Conclusions

Our approach to barrier-on-chip system fabrication based on double-sided pressure-sensitive adhesive tape proves to be both affordable and functional. For small intestine modeling, we obtain an epithelial barrier layer with tight cellular junctions across the entirety of the microfluidic channels. Cell polarization, barrier permeability, and junction protein expression are consistent with prior *in vitro* research both in Transwells and in traditional PDMS-based organs-on-chips. We further demonstrate biological response to chili peppers (capsaicinoids). Though devices and Transwells show different response in terms of permeability, our observations on metabolic impact as well as actin and tight junction protein localization align well with other *in vivo* and *in vitro* studies.

Our tape-based approach to barriers-on-chip cannot compete with PDMS devices in terms of design freedom and foregoes the biophysical advantages of soft materials. It moreover remains to be seen whether the tapes would be compatible with more sensitive cellular models (*e.g.* hiPSC-derived). Instead we provide a simple and accessible fabrication approach suitable for work with similarly (compared to *e.g.* hiPSC culture) much more affordable cell culture. Tape-based barriers-on-chips can be assembled in academic labs with minimal equipment cost. The well-developed film- and tape-converting processes available, combined with pick-and-place technology, should further make industrial manufacture feasible at much lower per-unit cost than existing systems. We therefore hope that tape-based barriers-on-chips will enable more labs in lower-resource environments to enter a field currently dominated by relatively few well-funded facilities.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We appreciate the support of Dr. Charles Vidoudez and the Harvard Center for Mass Spectrometry in the metabolomic analysis. We further appreciate the assistance of the staff at the Karolinska Institute Biomedicum Imaging Core. T. E. W. is grateful for funding from the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement “NeuroVU” (No. 797777). M. F. and E. F. G. J. S. acknowledge support from the Erasmus+ program of the European Union. A. H. acknowledges funding from the Knut and Alice Wallenberg



Foundation, Göran Gustafssons Stiftelse, and Forska utan Djurförsök.

## Notes and references

- 1 S. N. Bhatia and D. E. Ingber, *Nat. Biotechnol.*, 2014, **32**, 760–772.
- 2 Clarivate Analytics, Web of Science, <https://apps.webofknowledge.com/>, (accessed October 1, 2019).
- 3 Organisation for Economic Co-operation and Development, OECD Data, <https://data.oecd.org/>, (accessed October 1, 2019).
- 4 B. Zhang, A. Korolj, B. F. L. Lai and M. Radisic, *Nat. Rev. Mater.*, 2018, **3**, 257–278.
- 5 M. W. van der Helm, A. D. van der Meer, J. C. T. Eijkel, A. van den Berg and L. I. Segerink, *Tissue Barriers*, 2016, **4**, e1142493.
- 6 J. Chen, H. Liu, Y. Huang and Z. Yin, *J. Manuf. Process.*, 2016, **23**, 175–182.
- 7 K. M. Ko, Die-cut and method of manufacturing or assembling die-cuts from the components thereof, US8262962B2, 2012.
- 8 S. A. Ripley, D. I. Hirsch and W. F. Bader, Lamination apparatus and methods, US7432009B2, 2008.
- 9 D. Patko, Z. Mártonfalvi, B. Kovacs, F. Vonderviszt, M. Kellermayer and R. Horvath, *Sens. Actuators, B*, 2014, **196**, 352–356.
- 10 P. K. Yuen and V. N. Goral, *Lab Chip*, 2010, **10**, 384–387.
- 11 S. R. A. Kratz, C. Eilenberger, P. Schuller, B. Bachmann, S. Spitz, P. Ertl and M. Rothbauer, *Sci. Rep.*, 2019, **9**, 1–12.
- 12 I. Pereiro, A. F. Khartchenko, L. Petrini and G. V. Kaigala, *Lab Chip*, 2019, **19**, 2296–2314.
- 13 J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak and A. Cardona, *Nat. Methods*, 2012, **9**, 676–682.
- 14 P. Coupé, M. Munz, J. V. Manjón, E. S. Ruthazer and D. Louis Collins, *Med. Image Anal.*, 2012, **16**, 849–864.
- 15 B. M. Maoz, A. Herland, E. A. FitzGerald, T. Grevesse, C. Vidoudez, A. R. Pacheco, S. P. Sheehy, T.-E. Park, S. Dauth, R. Mannix, N. Budnik, K. Shores, A. Cho, J. C. Nawroth, D. Segrè, B. Budnik, D. E. Ingber and K. K. Parker, *Nat. Biotechnol.*, 2018, **36**, 865–874.
- 16 M. C. Chambers, B. Maclean, R. Burke, D. Amodei, D. L. Ruderman, S. Neumann, L. Gatto, B. Fischer, B. Pratt, J. Egertson, K. Hoff, D. Kessner, N. Tasman, N. Shulman, B. Frewen, T. A. Baker, M.-Y. Brusniak, C. Paulse, D. Creasy, L. Flashner, K. Kani, C. Moulding, S. L. Seymour, L. M. Nuwaysir, B. Lefebvre, F. Kuhlmann, J. Roark, P. Rainer, S. Detlev, T. Hemenway, A. Huhmer, J. Langridge, B. Connolly, T. Chadick, K. Holly, J. Eckels, E. W. Deutsch, R. L. Moritz, J. E. Katz, D. B. Agus, M. MacCoss, D. L. Tabb and P. Mallick, *Nat. Biotechnol.*, 2012, **30**, 918–920.
- 17 R. Tautenhahn, G. J. Patti, D. Rinehart and G. Siuzdak, *Anal. Chem.*, 2012, **84**, 5035–5039.
- 18 G. Libiseller, M. Dvorzak, U. Kleb, E. Gander, T. Eisenberg, F. Madeo, S. Neumann, G. Trausinger, F. Sinner, T. Pieber and C. Magnes, *BMC Bioinf.*, 2015, **16**, 118.
- 19 T. E. Winkler *et al.*, LC-MS data and analysis, DOI: 10.6084/m9.figshare.11848278.
- 20 H. Luan, F. Ji, Y. Chen and Z. Cai, *Anal. Chim. Acta*, 2018, **1036**, 66–72.
- 21 J. Chong, O. Soufan, C. Li, I. Caraus, S. Li, G. Bourque, D. S. Wishart and J. Xia, *Nucleic Acids Res.*, 2018, **46**, W486–W494.
- 22 V. Vovk and R. Wang, 2019, arXiv:1212.4966v5 Math Stat.
- 23 J. Chong, M. Yamamoto and J. Xia, *Metabolites*, 2019, **9**, 57.
- 24 H. J. Kim, D. Huh, G. Hamilton and D. E. Ingber, *Lab Chip*, 2012, **12**, 2165–2174.
- 25 B. N. G. Sajay, C. S. Yin and Q. Ramadan, *J. Micromech. Microeng.*, 2017, **27**, 124004.
- 26 E. Walter and T. Kissel, *Eur. J. Pharm. Sci.*, 1995, **3**, 215–230.
- 27 M. D. Peterson and M. S. Mooseker, *J. Cell Sci.*, 1992, **102**, 581–600.
- 28 L. C. Delon, Z. Guo, A. Oszmiana, C.-C. Chien, R. Gibson, C. Prestidge and B. Thierry, *Biomaterials*, 2019, **225**, 119521.
- 29 W. Shin, C. D. Hinojosa, D. E. Ingber and H. J. Kim, *iScience*, 2019, **15**, 391–406.
- 30 J. Cabellos, C. Delpivo, S. Vázquez-Campos and G. Janer, *Toxicol. In Vitro*, 2019, **59**, 70–77.
- 31 H. J. Kim and D. E. Ingber, *Integr. Biol.*, 2013, **5**, 1130–1140.
- 32 H.-Y. Tan, S. Trier, U. L. Rahbek, M. Dufva, J. P. Kutter and T. L. Andresen, *PLoS One*, 2018, **13**, e0197101.
- 33 H. J. Kim, H. Li, J. J. Collins and D. E. Ingber, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, E7–E15.
- 34 J. D. Irvine, L. Takahashi, K. Lockhart, J. Cheong, J. W. Tolan, H. E. Selick and J. R. Grove, *J. Pharm. Sci.*, 1999, **88**, 28–33.
- 35 L. R. Madden, T. V. Nguyen, S. Garcia-Mojica, V. Shah, A. V. Le, A. Peier, R. Visconti, E. M. Parker, S. C. Presnell, D. G. Nguyen and K. N. Retting, *iScience*, 2018, **2**, 156–167.
- 36 C. Zhang, *Master's thesis*, Northeastern University, 2019.
- 37 D. M. Wuest, A. M. Wing and K. H. Lee, *J. Neurosci. Methods*, 2013, **212**, 211–221.
- 38 S. Hinkel, K. Mattern, A. Dietzel, S. Reichl and C. C. Müller-Goymann, *Int. J. Pharm.*, 2019, **566**, 434–444.
- 39 K. Bittermann and K.-U. Goss, *PLoS One*, 2017, **12**, e0190319.
- 40 ChemAxon, Chemicalize, <http://www.chemicalize.com/>, (accessed October 1, 2019).
- 41 J. Küblbeck, J. J. Hakkarainen, A. Petsalo, K.-S. Vellonen, A. Tolonen, P. Reponen, M. M. Forsberg and P. Honkakoski, *J. Pharm. Sci.*, 2016, **105**, 941–949.
- 42 K. Srinivasan, *Crit. Rev. Food Sci. Nutr.*, 2016, **56**, 1488–1500.
- 43 E. Jensen-Jarolim, L. Gajdzik, I. Haberl, D. Kraft, O. Scheiner and J. Graf, *J. Nutr.*, 1998, **128**, 577–581.
- 44 H. Isoda, J. Han, M. Tominaga and T. Maekawa, *Cytotechnology*, 2001, **36**, 155–161.
- 45 J. Han, H. Isoda and T. Maekawa, *Cytotechnology*, 2002, **40**, 93–98.
- 46 J. K. Han, M. Akutsu, T. P. N. Talorete, T. Maekawa, T. Tanaka and H. Isoda, *Cytotechnology*, 2005, **47**, 89–96.



47 Y. Tsukura, M. Mori, Y. Hirotani, K. Ikeda, F. Amano, R. Kato, Y. Ijiri and K. Tanaka, *Biol. Pharm. Bull.*, 2007, **30**, 1982–1986.

48 Y. Nagumo, J. Han, A. Bellila, H. Isoda and T. Tanaka, *Biochem. Biophys. Res. Commun.*, 2008, **377**, 921–925.

49 J. Han, H. Isoda and J. Agric, *Food Chem.*, 2009, **57**, 11148–11153.

50 T. Shiobara, T. Usui, J. Han, H. Isoda and Y. Nagumo, *PLoS One*, 2013, **8**, e79954.

51 M. Kaiser, S. Pereira, L. Pohl, S. Ketelhut, B. Kemper, C. Gorzelanny, H.-J. Galla, B. M. Moerschbacher and F. M. Goycoolea, *Sci. Rep.*, 2015, **5**, 10048.

52 B. Rohm, A. Riedel, J. P. Ley, S. Widder, G. E. Krammer and V. Somoza, *Food Funct.*, 2015, **6**, 172–184.

53 P. Popelka, P. Jevinová, K. Šmejkal and P. Roba, *Folia Vet.*, 2017, **61**, 11–16.

54 L. Sherwood, *Human Physiology: From Cells to Systems*, Cengage Learning, 2008.

55 U. F. Arifin and M. Djaeni, *Bull. Chem. React. Eng. Catal.*, 2018, **13**, 365–372.

56 M. W. Toepke and D. J. Beebe, *Lab Chip*, 2006, **6**, 1484–1486.

57 R. Konsoula and F. A. Barile, *Toxicol. In Vitro*, 2005, **19**, 675–684.

58 J. L. Madara, *Annu. Rev. Physiol.*, 1998, **60**, 143–159.

59 S. Kim, S. C. LesherPerez, B. C. C. Kim, C. Yamanishi, J. M. Labuz, B. Leung and S. Takayama, *Biofabrication*, 2016, **8**, 015021.

60 V. Viranuvatti, C. Kalayasiri, O. Chearani and U. Plengvanit, *Am. J. Gastroenterol.*, 1972, **58**, 225–232.

61 C. Goso, S. Evangelista, M. Tramontana, S. Manzini, P. M. Blumberg and A. Szallasi, *Eur. J. Pharmacol.*, 1993, **249**, 185–190.

62 G. B. Glavin, *Gen. Pharmacol.*, 1992, **23**, 1023–1026.

63 C. Cochereau, D. Sanchez, A. Bourhaoui and E. E. Creppy, *Toxicol. Appl. Pharmacol.*, 1996, **141**, 133–137.

64 S. K. Panchal, E. Bliss and L. Brown, *Nutrients*, 2018, **10**, 630.

65 P. Ramamoorthy, S. Thomas, A. Ramachandran and K. A. Balasubramanian, *Dig. Dis. Sci.*, 2006, **51**, 466–470.

66 R. Prabhu, S. Thomas and K. A. Balasubramanian, *Arch. Biochem. Biophys.*, 2005, **434**, 299–305.

67 *Biology of Inositol and Phosphoinositides: Subcellular Biochemistry*, ed. A. L. Majumder and B. B. Biswas, Springer, US, Boston, MA, 2006, vol. 39.

